Real-time nucleic acid amplification-based qualitative assay for specific genotyping of E6/E7 mRNA from HPV 16, 18, 31, 33, and 45.
A useful tool to identify women at risk for developing Cervical Cancer.
PreTect HPV-Proofer 5® is based on NASBA technology, an enzymatic amplification process that can amplify and detect RNA even in the presence of DNA. Unlike PCR, an amplification run is performed under isothermal conditions at 41°C, achieving a fast result.
PreTect SEE® identifies three of the most important HR-HPV (16, 18, and 45) genotypes related to cervical cancer while PreTect HPV-Proofer 5® identifies five HR-HPV genotypes (16, 18, 31, 33, and 45).
PreTect HPV-Proofer 5® detects five of the most common HR-HPV genotypes related to cervical cancer. These five HR-HPV types are related to >80 % of all cervical cancer cases in the world.
PreTect HPV-Proofer 5® is clinically validated according to the EU IVD regulations.
We develop medical devices and safe, state-of-the-art molecular technologies that empower you to take control of your health through prevention.
Have Questions? Our team is happy to answer any questions you may have.